Semaglutide vs. Tirzepatide

Overview

Choosing between the two most prominent weight-loss medications requires looking beyond the price tag to efficacy, availability, and clinical data.

Key Metrics

Clinical Trial Data

Semaglutide (STEP-1 Trial): Participants lost an average of 14.9% body weight over 68 weeks. 86% achieved ≥5% weight loss, and 32% achieved ≥20% weight loss.

Tirzepatide (SURMOUNT-1 Trial): At the highest dose (15mg), participants lost an average of 20.9% body weight over 72 weeks. 96% achieved ≥5% weight loss, and 57% achieved ≥20% weight loss.

Side Effect Profile

Both medications share common GI side effects — nausea, vomiting, diarrhea, and constipation. These typically improve after the first 4-8 weeks of titration. Some patients report better GI tolerability with tirzepatide, though head-to-head data is limited.

Insurance & Access

Semaglutide has more established insurance pathways due to its longer time on the market. Tirzepatide coverage is expanding rapidly, especially through Eli Lilly’s LillyDirect self-pay program ($299–$449/mo for Zepbound).

How It Compares to Other Matchups

• Ozempic vs Wegovy — same drug (semaglutide), different FDA indications
• Mounjaro vs Zepbound — same drug (tirzepatide), different FDA indications
• Branded vs Compounded — cost comparison between FDA-approved and compounded versions

Frequently Asked Questions

Which drug is more effective for weight loss?

The clinical trial evidence consistently favors tirzepatide. In the SURMOUNT-1 trial, patients on tirzepatide 15 mg (the highest dose, branded as Zepbound) lost an average of 20.9% of body weight over 72 weeks — compared to approximately 14.9% for semaglutide 2.4 mg in the STEP-1 trial (Wegovy). That ~6% average difference translates to roughly 13 additional pounds of weight loss for a 220-pound patient. At the population level, 57% of tirzepatide patients lost ≥20% of body weight, versus 32% on semaglutide. The mechanistic explanation is tirzepatide’s dual GLP-1/GIP receptor activation, which engages two separate incretin pathways rather than one. In the SURPASS-2 head-to-head comparison (tirzepatide vs. semaglutide 1 mg, not 2.4 mg), tirzepatide showed statistically superior A1C reduction and weight loss at all dose comparisons. For maximum weight loss, tirzepatide has the stronger evidence base as of April 2026.

Can I switch from Semaglutide to Tirzepatide?

Yes — switching from semaglutide (Wegovy, Ozempic) to tirzepatide (Zepbound, Mounjaro) is one of the most common GLP-1 transitions in clinical practice, typically motivated by reaching a weight-loss plateau, insufficient glycemic control, or a desire for stronger outcomes. The switch is done under physician supervision. Because semaglutide and tirzepatide are different molecules with different potency profiles, there is no direct dose conversion formula — your physician will design a new titration schedule starting at a conservative tirzepatide dose based on your current semaglutide dose and tolerance history. Most patients don’t start from 2.5 mg but may begin at 5 mg depending on their GLP-1 experience. Expect mild re-emergence of GI side effects during the transition and titration period, which typically resolves within a few weeks. Clinical data suggests patients who respond to semaglutide but want more weight loss often achieve significant additional loss after transitioning to tirzepatide.

Which has fewer side effects?

Both semaglutide and tirzepatide share the same profile of common GI side effects — nausea, diarrhea, constipation, and occasional vomiting — which are a class effect of GLP-1 receptor activation. These are most prominent during dose escalation and typically resolve within 4–8 weeks of reaching a stable dose. Some patients and providers report better GI tolerability with tirzepatide, potentially related to the GIP receptor component modulating nausea signaling, but published head-to-head tolerability data is limited. In the SURMOUNT and STEP trials, discontinuation due to GI adverse events was approximately 4–6% for both drugs at the highest doses. Individual responses vary substantially — some patients who couldn’t tolerate semaglutide do well on tirzepatide, and vice versa. Regardless of which you choose, starting at the lowest dose and titrating slowly (staying at each dose level for 4 weeks before escalating) is the single most effective strategy for minimizing side effects.

Keep Reading

• Wegovy vs Zepbound — the weight-loss-specific versions compared
• Oral vs Injectable GLP-1 — considering a pill instead?
• Complete Guide to GLP-1 Costs — every access path and price compared